Comparative Safety Of Filgrastim Vs Other Hgfs

In a study comparing rates of adverse events with filgrastim vs sargramostim (rHuGM-CSF) when given prophylactically to patients receiving myelosuppressive chemotherapy, 490 patients treated for lung, breast, lymphatic system, or ovarian tumors were analyzed. The frequency and severity of adverse events were assessed. Fever unexplained by infection was more common with sargramostim (7% vs 1%; p < 0.001), as were fatigue and diarrhea; however, skeletal pain was more frequent with filgrastim. Overall, adverse events were less frequent with filgrastim than with sargramostim (40).

0 0

Post a comment